ImmunoGen and ImmunoBiochem Collaborate to Develop Advanced Antibody-Drug Conjugates

WALTHAM, Mass., July 24, 2023 (VSNewsNetwork.com) - ImmunoGen, Inc. and ImmunoBiochem Corporation have announced a multi-target license and option agreement. ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for cancer treatment, will combine its proprietary linker-payload technology with ImmunoBiochem's specific-target antibodies to explore novel ADCs. ImmunoBiochem, in exchange, will receive an upfront payment and is eligible for milestone payments and royalties based on pre-specified achievements.

ImmunoGen's Vice President of Clinical Development and Translational Sciences, Eric Westin, expressed the company's commitment, stating, "This agreement reflects our commitment to leverage our rich IP portfolio through strategic partnering in order to further reinvigorate our research and development in support of our pipeline." Dr. Anton Neschadim, CEO of ImmunoBiochem, welcomed the partnership, saying it validates their differentiated approach and enables expansion of their discovery platform and innovative pipeline. ImmunoGen will now assume responsibility for future clinical development and commercialization activities related to the program.

To learn more about this collaboration and ImmunoGen's other initiatives, visit www.immunogen.com.

Source: ImmunoGen, Inc. via Business Wire